Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer
Compass Therapeutics (Nasdaq: CMPX) has announced a webcast scheduled for April 1, 2025, at 8:00 AM ET to present top-line clinical data from their ongoing Phase 2/3 COMPANION-002 trial. The study evaluates tovecimig, a DLL4 x VEGF-A bispecific antibody, in combination with paclitaxel for treating patients with advanced biliary tract cancer (BTC).
The virtual event will be accessible via webcast, with a replay available for 90 days on Compass' Events page.
Compass Therapeutics (Nasdaq: CMPX) ha annunciato un webcast programmato per il 1 aprile 2025, alle 8:00 AM ET, per presentare i dati clinici preliminari del loro ongoing trial Fase 2/3 COMPANION-002. Lo studio valuta tovecimig, un anticorpo bispecifico DLL4 x VEGF-A, in combinazione con paclitaxel per il trattamento di pazienti con cancro avanzato delle vie biliari (BTC).
L'evento virtuale sarà accessibile tramite webcast, con una registrazione disponibile per 90 giorni sulla pagina Eventi di Compass.
Compass Therapeutics (Nasdaq: CMPX) ha anunciado un webcast programado para el 1 de abril de 2025, a las 8:00 AM ET, para presentar los datos clínicos preliminares de su ongoing ensayo Fase 2/3 COMPANION-002. El estudio evalúa tovecimig, un anticuerpo bispecífico DLL4 x VEGF-A, en combinación con paclitaxel para tratar a pacientes con cáncer avanzado de las vías biliares (BTC).
El evento virtual será accesible a través de un webcast, con una repetición disponible durante 90 días en la página de Eventos de Compass.
Compass Therapeutics (Nasdaq: CMPX)는 2025년 4월 1일 오전 8시 ET에 진행 중인 2/3상 COMPANION-002 시험의 주요 임상 데이터를 발표하기 위해 웹캐스트를 예정하고 있다고 발표했습니다. 이 연구는 tovecimig, DLL4 x VEGF-A 이중특이성 항체와 파클리탁셀을 병용하여 진행성 담도암(BTC) 환자를 치료하는 것을 평가합니다.
이 가상 이벤트는 웹캐스트를 통해 접근 가능하며, Compass의 이벤트 페이지에서 90일 동안 재생이 가능합니다.
Compass Therapeutics (Nasdaq: CMPX) a annoncé un webcast prévu pour le 1er avril 2025 à 8h00 ET pour présenter les données cliniques préliminaires de leur essai de Phase 2/3 COMPANION-002 en cours. L'étude évalue tovecimig, un anticorps bispécifique DLL4 x VEGF-A, en combinaison avec le paclitaxel pour traiter les patients atteints de cancer avancé des voies biliaires (BTC).
L'événement virtuel sera accessible via un webcast, avec un replay disponible pendant 90 jours sur la page Événements de Compass.
Compass Therapeutics (Nasdaq: CMPX) hat ein Webcast für den 1. April 2025 um 8:00 Uhr ET angekündigt, um die vorläufigen klinischen Daten aus ihrer laufenden Phase 2/3 COMPANION-002 Studie zu präsentieren. Die Studie bewertet tovecimig, einen DLL4 x VEGF-A bispezifischen Antikörper, in Kombination mit Paclitaxel zur Behandlung von Patienten mit fortgeschrittenem biliärem Krebs (BTC).
Die virtuelle Veranstaltung wird über einen Webcast zugänglich sein, mit einer Wiederholung, die 90 Tage lang auf der Veranstaltungsseite von Compass verfügbar ist.
- None.
- None.
- Webcast scheduled for Tuesday, April 1, 2025 at 8:00 AM ET.
BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced it will host a webcast on Tuesday, April 1, 2025 at 8:00 AM ET to review top-line clinical data from its ongoing Phase 2/3 COMPANION-002 clinical trial assessing tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel in patients with advanced biliary tract cancer (BTC).
Webinar Details:
Date: Tuesday, April 1, 2025
Time: 8 AM EDT
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1712286&tp_key=3b05c5ebcd
Virtual/Replay availability: A replay will be archived for 90 days on Compass’ Events page.
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.
Investor Contact
ir@compasstherapeutics.com
Media Contact
Anna Gifford, Chief of Staff
media@compasstherapeutics.com
617-500-8099
FAQ
What clinical trial data will Compass Therapeutics (CMPX) present on April 1, 2025?
What is tovecimig and how is it being tested in the CMPX COMPANION-002 trial?
How can investors access the CMPX clinical data webcast on April 1?
How long will the CMPX tovecimig clinical data presentation replay be available?
